Home | Contact | Directions
Bookmark and Share

Management

Keith Dionne, Ph.D.
President and Chief Executive Officer

Dr. Dionne joined Constellation as President and Chief Executive Officer in March 2012 after serving as Entrepreneur-in-Residence at Third Rock Ventures. Previously, he served as CEO of Surface Logix, Inc. and as President and CEO of Alantos Pharmaceuticals, leading the company's acquisition by Amgen in July 2007. Prior to joining Alantos, Dr. Dionne was with Millennium Pharmaceuticals, Inc., where he held positions of increasing responsibility, concluding his seven-year tenure as both Vice President of Research and Development Strategy and Vice President and General Manager, Technology Business. Before his tenure with Millennium, Dr. Dionne served as Head of Preclinical Research & Development, implants at ALZA Pharmaceuticals. Dr. Dionne began his career in biotechnology as one of four original scientists at CytoTherapeutics, Inc.  He has served as an Adjunct Professor in the Biomedical Department at Brown University and received both a Ph.D. in chemical engineering and M.S. in the program for technology policy from Massachusetts Institute of Technology.


James E. Audia, Ph.D.
Chief Scientific Officer

Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.


Michael R. Cooper, M.D. 
 Chief Medical Officer

Dr. Cooper joined Constellation Pharmaceuticals in 2011 as its Chief Medical Officer. Before joining Constellation Dr. Cooper held leadership positions at Novartis Pharmaceuticals, where he was Clinical Head of Oncology Translational Medicine in Cambridge, Massachusetts, and at Millennium Pharmaceuticals, where he was Vice President of Oncology Clinical Development. Before joining the pharmaceutical industry, Dr. Cooper practiced medical oncology and hematology in various academic institutions, where he led programs in the early clinical development of novel anti-cancer compounds. His interest in cancer pharmacology, pharmacokinetics and biomarker development was developed during his tenure as a Senior Clinical Investigator in the Clinical Pharmacology and Medicine Branches of the National Cancer Institute in Bethesda, Maryland. Dr. Cooper received his M.D. from Duke University School of Medicine, which is also where he completed his residency in internal medicine and his fellowship in hematology and medical oncology.


Brenda J. Sousa
Vice President of Human Resources

Ms. Brenda Sousa joined Constellation as Vice President of Human Resources for Constellation in March 2010.  Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices.  Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare.  Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing.  Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board.  Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.


Matthias Jaffe
Chief Financial Officer

Mr. Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role.  Previously, Mr. Jaffe served as CFO and VP of Business Development at Zafgen, a Third Rock Ventures’ portfolio company.  He has also held senior positions in a number of private, venture-backed companies in the life science and cleantech space, including Alantos Pharmaceuticals, which under the leadership of Dr. Dionne, was acquired by Amgen in 2007.  Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies.  He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues.  Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).